Scientific Foundation

Mitochondria are the energy-producing organelles found within nearly every human cell, and they carry their own distinct genome separate from the DNA contained in the cell nucleus. A key feature of mitochondrial DNA is that it is present in many copies per cell, sometimes numbering in the hundreds or thousands, which contrasts with the two copies of nuclear DNA found in most cells. This abundance can make mitochondrial DNA a potentially rich source of detectable signal when searching for disease-associated changes in a blood sample or other specimen.

MDNA Life Sciences bases its work on the observation that certain disease processes, including the development of cancer, are associated with specific alterations, deletions, and rearrangements within the mitochondrial genome. The company has investigated a particular category of mitochondrial DNA change that it associates with malignant and other disease states. By identifying and quantifying these mitochondrial signatures, the company aims to provide diagnostic insight that can complement or improve upon existing testing methods.

The Mitomic Technology Platform

The core of MDNA Life Sciences' business is its proprietary platform, which the company markets under the Mitomic name. This platform is built around the identification of mitochondrial DNA biomarkers and the translation of those biomarkers into practical, blood-based diagnostic assays. The intended advantage of a blood-based test is that it is minimally invasive compared with tissue biopsy procedures, potentially allowing for earlier and more convenient screening.

The Mitomic approach seeks to detect disease-associated mitochondrial DNA changes that may be present even at early stages of disease. The company has described its technology as being able to draw on the high copy number of mitochondrial DNA to detect signals that might otherwise be difficult to identify. This platform underpins the company's product development efforts across multiple disease areas.

Products and Areas of Focus

Prostate Cancer Testing

One of the most prominent products developed by MDNA Life Sciences is a mitochondrial DNA-based test aimed at prostate cancer. Prostate cancer screening has traditionally relied heavily on the prostate-specific antigen (PSA) blood test, which is known to produce a significant number of ambiguous or false-positive results, often leading to unnecessary biopsies. MDNA Life Sciences has positioned its prostate test as a tool intended to improve the accuracy of assessment and to help distinguish men who may need a biopsy from those who may not, thereby reducing unnecessary invasive procedures. The test analyzes mitochondrial DNA biomarkers from a blood sample.

Endometriosis Testing

The company has also applied its Mitomic technology to the challenge of endometriosis, a common and often painful gynecological condition that is notoriously difficult and slow to diagnose. Endometriosis frequently requires invasive laparoscopic surgery for definitive diagnosis, and many patients endure years of delay before receiving an accurate answer. MDNA Life Sciences has worked toward a blood-based test designed to detect mitochondrial DNA biomarkers associated with endometriosis, with the goal of providing an earlier, less invasive diagnostic option for affected women.

Broader Oncology and Disease Pipeline

Beyond prostate cancer and endometriosis, MDNA Life Sciences has expressed intentions to expand its platform into additional disease areas. The mitochondrial biomarker approach is, in principle, applicable to a range of cancers and other conditions where mitochondrial DNA changes may serve as detectable indicators. The company's research and development activities have therefore been oriented toward building a pipeline of tests that share the common technological foundation of mitochondrial DNA analysis.

Business Model and Services

As a molecular diagnostics company, MDNA Life Sciences generates value through the development, validation, and commercialization of laboratory tests. Its services are centered on providing diagnostic assays that clinicians and patients can use to inform medical decision-making. The company's activities typically encompass:

• Research into mitochondrial DNA biomarkers and their associations with specific diseases.
• Development of assays that translate biomarker discoveries into reproducible laboratory tests.
• Clinical validation studies designed to demonstrate the performance, sensitivity, and specificity of its tests.
• Efforts toward regulatory clearance and market adoption of its diagnostic products.

Market Position and Significance

MDNA Life Sciences occupies a specialized position within the broader diagnostics industry. While much of the liquid biopsy and blood-based diagnostics field has focused on circulating tumor DNA derived from the nuclear genome, MDNA Life Sciences has differentiated itself by concentrating on the mitochondrial genome. This focus reflects a wager that mitochondrial DNA changes can offer distinct and valuable diagnostic information, potentially enabling earlier detection and improved specificity in areas where existing tools fall short.

The company's emphasis on conditions with significant unmet diagnostic needs, such as the high false-positive rate associated with PSA testing in prostate cancer and the lengthy diagnostic journey experienced by many endometriosis patients, illustrates its strategy of targeting clinical problems where improved testing could have meaningful impact for patients and healthcare systems.

Summary

MDNA Life Sciences Inc. is a biotechnology and life sciences company dedicated to advancing molecular diagnostics through the analysis of mitochondrial DNA. Its proprietary Mitomic platform serves as the basis for a range of blood-based tests, with prostate cancer and endometriosis representing key focus areas. By exploiting the unique properties of the mitochondrial genome, the company seeks to deliver diagnostic tools that are less invasive, more informative, and capable of earlier disease detection than some conventional approaches. Through its research, assay development, and clinical validation efforts, MDNA Life Sciences aims to contribute to improved patient care in areas of significant medical need.